BioSpace News Archive

Drug Development

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

Zevra Therapeutics, Inc. today announced the acceptance of an Investigational New Drug (“IND”) application by the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy which is expected to provide additional information regarding the optimal dosing regimen.

May 3, 2023
·
6 min read
Drug Development

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Healthcare Ltd is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

May 3, 2023
·
1 min read
Genetown

Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH).

May 3, 2023
·
7 min read
Genetown

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

Dyne Therapeutics, Inc today announced that management is scheduled to participate in a fireside chat at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023 at 11:35 a.m. PT (2:35 p.m. ET).

May 3, 2023
·
1 min read
Drug Development

Affinia Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting

Affinia Therapeutics today announced that new preclinical data will be presented in an oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles, CA.

May 3, 2023
·
1 min read
Business

Neurocrine Biosciences Reports First Quarter 2023 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an update on its 2023 financial guidance.

May 3, 2023
·
14 min read
Business

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

Soligenix, Inc. announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors.

May 3, 2023
·
7 min read
Business

Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update.

May 3, 2023
·
1 min read
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Small Pharma Inc. is pleased to announce that Dr. Carol Routledge, Chief Medical and Scientific Officer, will deliver a poster presentation at the 34th CINP World Congress of Neuropsychopharmacology in Montreal, Canada which is taking place on May 7-10, 2023.

May 3, 2023
·
2 min read
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS ® (Voclosporin) For Adults with Active Lupus Nephritis.

May 3, 2023
·
7 min read